Taiwan Exosome CO., LTD. was established in 2021, dedicated to the horizontal and vertical development of novel new drugs utilizing human, animal, and plant exosomes, and conducting in-depth scientific research and development on exosome industrial technologies. Based on the most professional knowledge, equipment, and cutting-edge technology, the company develops treatments for intractable diseases, including autoimmune diseases and sarcopenia, and has established a "Pharmaceutical-Grade Exosome Industrial Technology Platform." This platform module builds technologies for exosome isolation, purification, identification, and mass production, positioning the company as a pioneer spanning the upstream, midstream, and downstream of the regenerative medicine industry chain.
The scientific research team is led in scientific and basic medical research by Dr. Yin-Ching Chuang, the first person in Taiwan to obtain information on COVID-19, former superintendent of Chi Mei Medical Center in Liouying, and a renowned infectious disease expert, in collaboration with Dr. Zhen-Xing Chen, a leading figure in the medical community, a Doctor of Medicine from Johns Hopkins University, and a senior advisor to the World Health Organization's Collaborating Center for Southern Europe.
The team also includes the laboratory of Chi Mei Medical Center in Liouying, the laboratory of the Department of Biochemical Science and Technology at National Taiwan University's College of Life Science, as well as dozens of global medical authorities (such as from the United States, Canada, Mainland China, etc.), high-level technical scientists, and numerous experienced scholars who have jointly dedicated themselves to this research.